STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[144] Sera Prognostics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Sera Prognostics insider Paul Kearney filed a Form 144 to sell 6,460 Class A common shares of SERA, representing an aggregate market value of $16,410. The securities were acquired by restricted stock unit vesting on 08/08/2025 and the proposed sale is also dated 08/08/2025. The sale is to be executed through Morgan Stanley Smith Barney. The filing reports 38,061,868 shares outstanding for the issuer, giving context to the size of this sale.

The form also discloses two recent sales by the same person: 7,089 shares on 05/08/2025 (gross proceeds $17,315) and 1,311 shares on 06/10/2025 (gross proceeds $1,946). The notice includes the standard insider representation that no undisclosed material adverse information is known to the seller.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Insider sale of 6,460 SERA shares is disclosed; size is immaterial relative to total shares outstanding.

The Form 144 shows Paul Kearney intends to sell 6,460 Class A shares with an aggregate value of $16,410, acquired via RSU vesting on the same date as the proposed sale. Compared with the issuer's 38,061,868 outstanding shares, this represents a negligible fraction of equity. Two prior small sales in May and June are also reported. From a financial-impact perspective, this filing is routine and unlikely to move valuation metrics or market perception materially.

TL;DR: Filing documents compliant insider sale activity; disclosure meets Rule 144 requirements and includes required seller representations.

The notice identifies the broker and shows the securities were acquired through restricted stock unit vesting, with sale execution via a registered broker-dealer, which aligns with standard compliance practice. The seller attests there is no undisclosed material adverse information. Given the small size of the transaction and prior recent disposals, this filing appears to be routine insider liquidity rather than a governance red flag.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the SERA Form 144 filed by Paul Kearney report?

The filing reports a proposed sale of 6,460 Class A common shares of Sera Prognostics by Paul Kearney, with an aggregate market value of $16,410.

When were the shares acquired and when is the proposed sale date in the Form 144?

The shares were acquired by restricted stock unit vesting on 08/08/2025, and the proposed sale date is also 08/08/2025.

Through which broker will the SERA shares be sold?

The filing identifies Morgan Stanley Smith Barney as the broker-dealer to execute the sale.

Has the filer sold SERA shares recently prior to this Form 144?

Yes. The filing discloses prior sales of 7,089 shares on 05/08/2025 (gross proceeds $17,315) and 1,311 shares on 06/10/2025 (gross proceeds $1,946).

How large is this sale compared with Sera Prognostics' outstanding shares?

The issuer has 38,061,868 shares outstanding, so the 6,460-share notice represents a very small fraction of total shares.
Sera Prognostics, Inc.

NASDAQ:SERA

SERA Rankings

SERA Latest News

SERA Latest SEC Filings

SERA Stock Data

130.45M
33.40M
10.8%
64.96%
1.88%
Medical Devices
Services-medical Laboratories
Link
United States
SALT LAKE CITY